Previous 10 | Next 10 |
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress PR Newswire — Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orex...
2023-10-04 12:32:07 ET More on Harmony Biosciences Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep Harmony Biosciences Holdings, Inc. 2023 Q2 - Results - Earnings Call Presentation Harmony Biosciences Holdings, Inc. (HRMY) Q2 2023 Earnings Call Tran...
NORTHAMPTON, MA / ACCESSWIRE / September 21, 2023 / Alkermes September is Ovarian Cancer Awareness Month. We stand in solidarity with patients, caregivers and family members whose lives have been impacted by Ovarian Cancer. Our oncology team is dedicated to advancing research and developing pot...
NORTHAMPTON, MA / ACCESSWIRE / September 19, 2023 / The Alkermes Pathways Research Awards are open for applications! This program is open to all early-career investigators studying bipolar disorder or schizophrenia. With millions of people impacted by neurological disorders, more research is ur...
NORTHAMPTON, MA / ACCESSWIRE / September 18, 2023 / Alkermes On World Suicide Prevention Day, we remember all those affected by suicide. In 2020, the United States had 1 death by suicide every 11 minutes. But help is available. If you or someone you know is in crisis, dial 988 to find help and...
Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress PR Newswire — Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy — DUBLIN , Sept. 11, 2023 /PRNe...
- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project - - Application Period to Run From Sept. 15, 2023 Through Nov. 30, 2023 - DUBLIN, IRELAND / ACCESSWIRE / September 7, 2023 / Alkermes plc (Nasdaq:ALKS) announced that it will begin accepting applic...
Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program PR Newswire — Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Application Period to Run From Sept. 15, 2023 ...
Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program PR Newswire – Competitive Grants Program Awards Funding to 11 Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer – DUBLIN ...
2023-08-30 10:38:05 ET More on Alkermes Alkermes: A Complicated Story Right Now Lybalvi: Weighing In Light, But Tipping Alkermes' Scales Alkermes plc 2023 Q2 - Results - Earnings Call Presentation Alkermes plc ( ALKS ) Q2 2023 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...